Systemic sclerosis sine scleroderma (ssSSc) affects nearly 10% of patients with systemic sclerosis (SSc), with substantial internal organ involvement. Despite lacking skin fibrosis, patients with ...

CARLSBAD, California — In 2003, researchers asked 303 patients with systemic sclerosis (scleroderma) what bothered them most about their disease from an aesthetic standpoint: Orofacial features, such ...

Systemic sclerosis is an autoimmune disease that is characterized by the distinctive pathogenetic triad of microvascular damage, dysregulation of innate and adaptive immunity, and generalized fibrosis ...

The scleroderma skin pinch test checks the thickness and elasticity of your skin. It can help doctors diagnose and monitor scleroderma, an autoimmune condition that causes inflammation and thickening ...

Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell ...

What is systemic sclerosis (scleroderma) and who does it affect? Systemic sclerosis, also known as scleroderma, is a rare disease characterized by the thickening and scarring of connective tissue of ...

Please provide your email address to receive an email when new articles are posted on . Scleroderma and other connective tissue diseases such as systemic lupus erythematosis, dermatomyositis, Behçet’s ...

Most people with scleroderma have autoantibodies. Several scleroderma-specific antibodies have been identified. These can help with diagnosis and give insight into the type of disease you may ...

Angiotensin-converting enzyme (ACE) inhibitors are the mainstay of therapy for patients with systemic sclerosis in scleroderma renal crisis, however mortality remains high even in the post-ACE ...

Scleroderma is a range of disorders in which the skin and connective tissues tighten and harden. It is a long-term, progressive disease. This means it gradually gets worse. Share on Pinterest ...

The U.S. Food and Drug Administration granted the first approval for a drug to slow the decline of pulmonary function in interstitial lung disease associated with systemic sclerosis or scleroderma ...